SCHEMBL710475

SCHEMBL710475

Cc1cccc(C=CC=Cc2ccccn2)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.58
NPC1 O15118 5/20 0.58
ALDH1A1 P00352 3/20 0.58
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
GRM4 Q14833 3/20 0.58
KDM4E B2RXH2 3/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
GRM5 P41594 2/20 0.58
NPSR1 Q6W5P4 2/20 0.58
PKM P14618 2/20 0.58
HDAC6 Q9UBN7 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2D6 P10635 1/20 0.58
CYP2C9 P11712 1/20 0.58
HPGD P15428 1/20 0.58
TSHR P16473 1/20 0.58
NFKB1 P19838 1/20 0.58
CYP2C19 P33261 1/20 0.58
THPO P40225 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL710474 1.00 RAB9A (0.58) RAB9ANPC1ALDH1A1MEN1KMT2A
SCHEMBL4711050 0.92 RAB9A (0.67) RAB9ANPC1ALDH1A1MEN1KMT2A
SCHEMBL4711051 0.92 RAB9A (0.67) RAB9ANPC1ALDH1A1MEN1KMT2A
SCHEMBL721181 0.82 MEN1 (0.79) RAB9ANPC1ALDH1A1MEN1KMT2A
SCHEMBL721182 0.82 MEN1 (0.79) RAB9ANPC1ALDH1A1MEN1KMT2A
SCHEMBL2553913 0.81 ALDH1A1 (0.56) RAB9ANPC1ALDH1A1MEN1KMT2A
SCHEMBL2553909 0.81 ALDH1A1 (0.56) RAB9ANPC1ALDH1A1MEN1KMT2A
2-Pyridinecarboxaldehyde SCHEMBL3431231 0.80 ALDH1A1 (0.47) RAB9ANPC1ALDH1A1MEN1KMT2A
SCHEMBL708570 0.80 MEN1 (0.75) RAB9ANPC1ALDH1A1MEN1KMT2A
SCHEMBL708571 0.80 MEN1 (0.75) RAB9ANPC1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124625-B2 enhancing the expression of apoAI; prevention or therapy of dislipidemia SHIONOGI & CO., LTD. (JP) 2012-02-28 US disclosed
US-8053445-B2 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2011-11-08 US disclosed
US-20090036457-A1 Utilities of olefin derivatives YAMAMORI TERUO 2009-02-05 US disclosed
US-20040242615-A1 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242615-A1 Utilities of olefin derivatives APOL1, NR1H2, APOB RAB9A 4723/4885NPC1 19/4885ALDH1A1 1967/4885
US-20090036457-A1 Utilities of olefin derivatives APOL1, APOB, NR1H2 RAB9A 4606/4885NPC1 48/4885ALDH1A1 1938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.